The Formedix Clinic

Drop in and catch up on the latest news and standards knowledge. No appointment necessary.

The Formedix Clinic > End-to-End Clinical Trials

Optimizing an End-to-End Clinical Trial in 3 Steps

26 August 2015
by Fiona Hartley About The Author

Paris in the summer: a city brimming with life, stunning architecture… and scintillating CDISC discussion. In June, our Consultancy Team Lead Ed flew to the City of Light to meet our technology partners OmniComm and participate in their Collaborative Clinical Insights Symposium. With the focus on achieving operational efficiencies in clinical trials, Ed’s talk focussed on the cost-effective implementation of the Study Data Tabulation Model (SDTM) standard. We sat down with Ed to discuss the standard, and teased out of him three essential steps for optimizing an end-to-end clinical trial.

Read More

Instant gratification is everywhere. Are clinical trials ready?

7 August 2015
by Fiona Hartley About The Author

There’s much to marvel at - and just as much to dislike - in our culture of instant gratification.

Read More

15 Changes in Clinical Trials Since 2000: Part 2

16 March 2015
by Fiona Hartley About The Author

We’re celebrating the 15th Anniversary of Formedix this year. It got us thinking about how the clinical trials world has changed since we've been around: sometimes it feels like little has changed in 15 years, but often it feels like the pace of change is unsustainable. This is the second in our three-part series - part one is here, and part three is here. Read on for part two of our top 15 things that have changed in clinical trials since 2000.

Read More

The Monday Morning Briefing: Asset Swaps, New Chairmen and Federal Citations

2 March 2015
by Fiona Hartley About The Author

Morning! It's now March (how did that happen?) but Spring hasn't quite yet sprung here at Formedix UK. However, just like permanently-rainy streets of Glasgow, the well of pharma industry news never runs dry. Read on to find out which giants are trading assets and settling in new chairmen, and which treatments are in trouble after being cited by a federal study.

Read More

Mark Wheeldon Discusses CDISC Standards From the Start: Part 2

22 January 2015
by Fiona Hartley About The Author

This is the second of a two-part blog discussing CDISC standards from the start with Formedix CEO Mark Wheeldon. If you haven't read the first part yet, you'll find it here. Below are the slides from Mark's CDISC International Interchange 2014 presentation, CDISC: Standards from the Start, which accompany the discussion.

Read More

The Monday Morning Briefing: FDA, Ebola, J&J and more

5 January 2015
by Fiona Hartley About The Author

Good morning and welcome to the start of another working year! I’m not sure about you but boy, we’ve missed the office over these past 12 days. We’ve been on top of the latest developments in the pharma world, but it’s understandable that you might have been distracted. So with that in mind, here are the five biggest pharma news stories that emerged over the holiday period.

Read More

The Monday Morning Briefing - breaking pharma news

17 November 2014
by Fiona Hartley About The Author

Good morning! There’s a tonne of pharma news to get through this Monday - so let’s get straight to it, shall we?

Read More

Monday Morning Briefing: the pharma news you need to know

8 September 2014
by Fiona Hartley About The Author

It's the first Monday Morning Briefing since Labor Day, so today's news has a distinctly darker-than-normal hue. Here are the breaking pharma stories you need to know about this morning.

Read More

Fast and Flexible Standards with CDISC

26 May 2014
by Jim Garety About The Author

Case report forms (CRFs) are not exempt from the watchful eye of standards; they collect data from clinical research studies in a structured fashion. Their credibility exists primarily because they are regulated by peer reviewed standards.

Read More

Big Data to Improve ClinicalTrials.gov

24 April 2014
by Greg Blincow About The Author

There has been a major focus in the past couple of years on improvements and innovations in the drug development industry. CDISC is a massive contributor to this as its standards continue to help companies regulate various aspects of their clinical trials. This should perhaps be expected from a not-for-profit organization with the goal of improving the collection, exchange and submission of clinical research data, but are the big pharmaceutical companies doing their part to help the cause?

Read More